386 filings
Page 10 of 20
D
3cl7jxmi
9 Mar 21
$3.87M in equity / options, 18 investors
12:00am
6-K
yrtepcmzhx guiapi0
2 Mar 21
Current report (foreign)
4:07pm
6-K
or6lxf4oahcrxc24yp0
2 Mar 21
Report of Foreign Private Issuer
4:05pm
6-K
iob0p24hv2knwvjj32r
1 Mar 21
Current report (foreign)
4:00pm
6-K
szmh0lm4ens4 ap9tc7
24 Feb 21
SciSparc Corporate Presentation February 2021
9:27am
6-K
xoucvzg nznyo018rw
17 Feb 21
Report of Foreign Private Issuer
8:35am
6-K
ndicp6grp17
11 Feb 21
SciSparc Announces Rebranding and Business Updates
10:01am
6-K
cnfr xbzjcpm2wd3
10 Feb 21
SciSparc Engages Procaps for Development and Production of CannAmideā¢ and its SCI-110 Product Candidate
8:33am
6-K
6b2h okv0yd5pt
9 Feb 21
SciSparc Initiates Commercial Production of its CannAmideā¢ Pills
8:36am
424B3
10q0us
3 Feb 21
Prospectus supplement
12:10pm
6-K
7dxo7yj at3o5r7kkvlm
28 Jan 21
Report of Foreign Private Issuer
9:36am
6-K
yo3zk0 dbhbk
25 Jan 21
Special General Meeting of Shareholders
5:27pm
6-K
1e261e6iu
7 Jan 21
Report of Foreign Private Issuer
5:00pm
6-K
qbo3g2dfld8kn9tx
6 Jan 21
Report of Foreign Private Issuer
11:53am
6-K
83tgropo2p
5 Jan 21
Therapix Biosciences and Cyntar Ventures Entered a Non-Binding Letter of Intent for the Distribution of TheraPEA in Canada
9:12am
6-K
c1rlpayh9bwrmt2z3
31 Dec 20
Report of Foreign Private Issuer
2:02pm
6-K
438pp
15 Dec 20
Report of Foreign Private Issuer
10:55am
6-K
ywkw4epx3kf0rz
8 Dec 20
Therapix Biosciences Announces Upgrade to OTCQB Venture Market
9:36am
6-K
ezhay
2 Dec 20
Special General Meeting of Shareholders
4:02pm
6-K
3lmztv
2 Dec 20
Therapix Biosciences to Collaborate with The University of Calgary to Further Examine its Proprietary Drug Candidate THX-160 for Pain
9:25am